According to CoinMeta, Triad Therapeutics has signed a collaboration and licensing agreement with Johnson & Johnson. On October 9th, Triad Therapeutics, Inc. announced that the company and its wholly-owned subsidiary, Triad Therapeutics Technology Co., Ltd., have signed a collaboration and licensing agreement with Johnson & Johnson. The two parties will jointly develop new oral medications. Johnson & Johnson's venture capital arm, Janssen Ventures, will also make an equity investment in Triad Therapeutics.